Kytopen, a biotechnology company that develops and markets advanced cell engineering solutions, appointed Michael Chiu, Chief Executive Officer. An entrepreneurial leader with extensive experience in building and commercializing new technologies, Chiu brings a proven track record in fundraising, product development, and marketing launches. Chiu succeeds Paulo Garcia, one of the company's co-founders, who will continue as an advisor.
Kytopen., a transformative biotechnology company offering non-viral delivery that links the discovery, development and manufacturing of engineered cell therapies, today announced it was awarded a SBIR Fast Track grant from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institute of Health (NIH). Kytopen is eligible for up to $2M over the course of the 3-year award as project milestones are successfully completed within the Phase I and Phase II portions of the grant.
Market Place
Share